Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2015	Nov. 13, 2015
Document And Entity Information
Entity Registrant Name	MELA SCIENCES, INC. /NY
Entity Central Index Key	0001051514
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		10,183,393
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2015

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 3,169	$ 11,434
Restricted cash	100	0
Accounts receivable, net of allowance for doubtful accounts of $42 and $95, respectively	4,182	220
Inventories, net	3,915	5,275
Prepaid expenses and other current assets	596	274
Total current assets	11,962	17,203
Property and equipment, net	14,461	1,961
Patents and licensed technologies, net	7,490	37
Other intangible assets, net	8,190	0
Goodwill	8,928	0
Deferred financing costs	1,029	821
Other assets	94	48
Total assets	52,154	20,070
Current Liabilities:
Senior Note payable	8,848	0
Note payable	39	0
Accounts payable (includes $0 and $74 of related parties, respectively)	4,193	1,185
Other accrued liabilities	1,920	959
Deferred revenues	267	43
Total current liabilities	15,267	2,187
Long-term liabilities:
Senior secured convertible debentures, net	11,373	5,001
Warrant liability	9,535	499
Other liabilities	103	107
Total liabilities	36,278	7,794
Commitment and contingencies
Stockholders' equity:
Preferred Stock, $.10 par value, 10,000,000 shares authorized; 6,505 and 11,787 shares issued and outstanding, respectively	1	1
Common Stock, $.001 par value, 150,000,000 shares authorized; 9,887,358 and 6,037,232 shares issued and outstanding, respectively	10	6
Additional paid-in capital	222,502	194,562
Accumulated deficit	(206,647)	(182,293)
Accumulated other comprehensive income	10	0
Total stockholders' equity	15,876	12,276
Total liabilities and stockholders' equity	$ 52,154	$ 20,070

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Sep. 30, 2015	Dec. 31, 2014
Current Assets:
Allowance for doubtful accounts, current	$ 42	$ 95
Current Liabilities:
Accounts payable, related parties	$ 0	$ 74
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	6,505	11,787
Preferred stock, shares outstanding (in shares)	6,505	11,787
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	9,887,358	6,037,232
Common stock, shares outstanding (in shares)	9,887,358	6,037,232

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME [Abstract]
Revenues	$ 8,323	$ 218	$ 9,015	$ 541
Cost of revenues	3,042	1,560	10,226	3,755
Gross profit (loss)	5,281	(1,342)	(1,211)	(3,214)
Operating expenses:
Engineering and product development	471	345	946	1,423
Selling and marketing	4,001	429	5,984	2,366
General and administrative	3,132	1,885	6,819	5,988
Total operating expenses	7,604	2,659	13,749	9,777
Operating loss before other income (expense), net	(2,323)	(4,001)	(14,960)	(12,991)
Other income (expense), net:
Interest expense, net	(5,577)	(527)	(8,738)	(528)
Change in fair value of warrant liability	(1,329)	2,108	(679)	7,151
Gain on sale of assets	0	11	0	16
Registration rights liquidated damages			0	(3,420)
Other (loss) income, net	(5)	121	23	131
Nonoperating Income (Expense)	(6,911)	1,713	(9,394)	3,350
Net income (loss)	(9,234)	(2,288)	(24,354)	(9,641)
Deemed dividend related to warrant modification	(2,962)	0	(2,962)	0
Net loss attributable to common stockholders	(12,196)	(2,288)	(27,316)	(9,641)
Basic and diluted net loss per share (in dollars per share)	$ (1.29)	$ (0.44)	$ (3.42)	$ (1.89)
Shares used in computing basic and diluted net loss per share (in shares)	9,442,022	5,216,290	7,994,012	5,108,418
Other comprehensive income:
Foreign currency translation adjustments	10	0	10	0
Comprehensive loss	$ (12,186)	$ (2,288)	$ (27,305)	$ (9,641)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited) (USD $) In Thousands, except Share data	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Beginning balance at Dec. 31, 2014	$ 1	$ 6	$ 194,562	$ (182,293)	$ 0	$ 12,276
Beginning balance (in shares) at Dec. 31, 2014	11,787	6,037,232
Stock-based compensation	0	0	1,483	0	0	1,483
Conversion of convertible preferred stock	0	2	(2)	0	0	0
Conversion of convertible preferred stock (in shares)	(5,282)	2,059,455
Conversion of senior secured convertible debentures	0	2	4,591	0	0	4,593
Conversion of senior secured convertible debentures (in shares)	0	1,790,671
Discount on senior secured convertible debentures	0	0	27,300	0	0	27,300
Modification of warrants	0	0	(5,399)	0	0	(5,399)
Deemed dividend contribution to additional paid-in capital	0	0	2,962		0	2,962
Deemed dividend distribution from additional paid-in capital	0	0	(2,962)	0	0	(2,962)
Registration costs	0	0	(33)	0	0	(33)
Other comprehensive income	0	0	0	0	10	10
Net loss	0	0	0	(24,354)	0	(24,354)
Ending balance at Sep. 30, 2015	$ 1	$ 10	$ 222,502	$ 206,647	$ 10	$ 15,876
Ending balance (in shares) at Sep. 30, 2015	6,505	9,887,358

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash Flows From Operating Activities:
Net loss	$ (24,354)	$ (9,641)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,348	1,371
Provision for doubtful accounts	20	1
Stock-based compensation	1,483	447
Gain on disposal of property and equipment	0	(16)
Impairment of long-lived assets	920	0
Amortization of debt discount	7,571	385
Amortization of deferred financing costs	373	38
Inventory write-offs	4,818	1,076
Change in fair value of warrant liability	679	(7,151)
Changes in operating assets and liabilities:
Restricted cash	(100)	0
Accounts receivable	(300)	(29)
Inventories	(295)	(1,362)
Prepaid expenses and other assets	(321)	262
MelaFind systems sold	0	163
Accounts payable and accrued expenses	289	(40)
Other accrued liabilities	(150)	0
Other liabilities	(39)	66
Deferred revenues	13	(238)
Net cash used in operating activities	(7,045)	(14,668)
Cash Flows From Investing Activities:
Lasers placed-in-service, net	(1,066)	0
(Purchases) proceeds on sale of property and equipment	(17)	17
Acquisition of a business, net of cash acquired of $0	(42,500)	0
Net cash (used in) provided by investing activities	(43,583)	17
Cash Flows From Financing Activities:
Proceeds from convertible debentures	32,500	15,000
Proceeds from senior notes	10,000	0
Payments on notes payable	(20)	0
Registration costs	(134)	0
Expenses related to financing	0	(1,123)
Proceeds from private placement/public offerings	0	11,458
Net cash provided by financing activities	42,346	25,335
Effect of exchange rate changes on cash	17	0
Net (decrease)/increase in cash and cash equivalents	(8,265)	10,684
Cash and cash equivalents, beginning of period	11,434	3,783
Cash and cash equivalents, end of period	3,169	14,467
Supplemental information:
Cash paid for interest	402	0
Supplemental information of non-cash investing and financing activities
Establishment of a warrant liability with a deemed dividend	2,962	0
Conversion of senior secured convertible debentures into common stock	4,593	0
Reclassification of property and equipment to inventory, net	107	0
Reclassification of warrant liability to stockholders' equity	(5,399)	0
Recognition of debt discount and beneficial conversion feature on long-term debt	27,300	10,353
Exchange of series A convertible preferred stock for series B convertible preferred stock	$ 0	$ 12,300

The Company

9 Months Ended

Sep. 30, 2015

The Company [Abstract]

The Company

Note 1

The Company:

Background

MELA Sciences, Inc. (and its subsidiary) ("MELA" or "we" or the "Company") is a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological disorders. In June 2015 the Company completed the acquisition of the XTRAC excimer laser and the VTRAC excimer lamp businesses from PhotoMedex, Inc. The XTRAC® and VTRAC® products are FDA cleared devices for the treatment of psoriasis, vitiligo and other skin disorders. The purchase price was $42,500 plus the assumption of certain business-related liabilities. Management believes that the cash flow generated by these businesses will be sufficient to finance the Company's operations for the foreseeable future.

The XTRAC is an ultraviolet light excimer laser system utilized to treat psoriasis, vitiligo and other skin diseases. The XTRAC received FDA clearance in 2000 and has since become recognized treatment among dermatologists. The system delivers targeted 308um ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. As of September 30, 2015, there were 698 XTRAC systems placed in dermatologists' offices in the United States. The systems generate recurring revenue whereby the XTRAC system is placed in a physician's office and revenue is recognized on a per procedure basis. The XTRAC system's use for psoriasis is covered by nearly all major insurance companies, including Medicare. The VTRAC Excimer Lamp system, offered internationally, provides targeted therapeutic efficacy demonstrated by excimer technology with the simplicity of design and reliability of a lamp system.

The financial results of the XTRAC and VTRAC businesses have been included in the results of operations subsequent to June 22, 2015, the date of the acquisition. The assets of the businesses purchased and liabilities assumed have been consolidated as of June 22, 2015. (See Note 2, Acquisition.)

To finance the purchase of the XTRAC and VTRAC businesses, in June 2015 the Company entered into a securities purchase agreement with institutional investors (the "Purchasers") in connection with a private placement (the "2015 Financing"). The Company sold $10,000 aggregate principal amount of Notes bearing interest at 9% per year, with a maturity date of the earlier of 30 days after the Company obtains stockholder approval of stock issuances under the Debentures and the Warrants or November 30, 2015. The matter was approved by the stockholders' at the Company's annual meeting held September 30, 2015. Accordingly, the Notes mature 30 days from that approval, October 30, 2015. The Purchasers of the Notes were issued Warrants to purchase an aggregate of 3.0 million shares of the Company's common stock, having an exercise price of $0.75 per share. The Company also issued $32,500 aggregate principal amount of Senior Secured Convertible Debentures ("Debentures") that, subject to certain ownership limitations and stockholder approval conditions, will be convertible into 43,333,334 shares of common stock at an initial conversion price of $0.75 per share. The Debentures bear interest at the rate of 2.25% per year, and, unless previously converted, will mature on the five-year anniversary of the date of issuance. The Company's obligations under the Notes and Debentures (collectively, the "Debt Securities"), except for $500 of Debentures, are secured by a first priority lien on all of the assets, except for a second lien on the intellectual property. Under the terms of the Debentures and the Warrants, the issuances of shares of the common stock, including the Shares upon conversion of the Debentures and upon exercise of the Warrants, are subject to stockholder approval, which was received on September 30, 2015. Effective upon that date, the Company repriced outstanding Warrants held by certain investors to reduce the exercise price to $0.75 per share.

Liquidity

As of September 30, 2015, the Company had an accumulated deficit of $206,647 and has incurred losses since inception. To date, the Company has dedicated most of its financial resources to research and development, sales and marketing, and general and administrative expenses.

The Company has experienced recurring losses and negative cash flow from operations. The Company has been dependent on raising capital from the sale of securities in order to continue to operate and to meet its obligations in the ordinary course of business. The Company plans to refinance the Notes that became due October 30, 2015 with longer term debt, the terms and availability of which the Company cannot determine at this time. The Company is currently evaluation alternatives, including discussions with lenders, to refinance this debt. The timing and availability of any such refinancing cannot be assured and will be affected by numerous factors, many of which are not under our control. There can be no assurance that we will be able to raise additional funding as may be needed or on terms that are acceptable to the Company. These factors raise substantial doubt about the Company's ability to continue as a going concern. The Company has not made any adjustments to its condensed consolidated financial statements with respect to this uncertainty.

Basis of Presentation:

Accounting Principles

The accompanying condensed consolidated financial statements and related notes should be read in conjunction with the financial statements and related notes contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014 ("fiscal 2014"). The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC") related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company's financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.

The results for the three and nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015 or for any other interim period or for any future period.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.

Reclassification

Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have material impact on the Company's equity, net assets, results of operations or cash flows.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the US requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of September 30, 2015, the more significant estimates include (1) revenue recognition, including deferred revenues and valuation allowances of accounts receivable, (2) valuation of intangible assets, (3) warrant liabilities, (4) stock-based compensation and (5) the valuation allowance related to deferred tax assets.

Revenue Recognition

The Company recognizes revenues from product sales when the following four criteria have been met: (i) the product has been delivered and the Company has no significant remaining obligations; (ii) persuasive evidence of an arrangement exists; (iii) the price to the buyer is fixed or determinable; and (iv) collection is reasonably assured. Revenues from product sales are recorded net of provisions for expected returns and cash discounts.

The Company ships most of its products FOB shipping point, although from time to time certain customers, for example governmental customers, will be granted FOB destination terms. Among the factors the Company takes into account when determining the proper time at which to recognize revenue are (i) when title to the goods transfers and (ii) when the risk of loss transfers. Shipments to distributors or physicians that do not fully satisfy the collection criteria are recognized when invoiced amounts are fully paid or fully assured and included in deferred revenues until that time.

For revenue arrangements with multiple deliverables within a single, contractually binding arrangement (usually sales of products with separately priced extended warranty), each element of the contract is accounted for as a separate unit of accounting when it provides the customer value on a stand-alone basis and there is objective evidence of the fair value of the related unit.

The Company has two distribution channels for its phototherapy treatment equipment. The Company either (i) places its lasers in a physician's office (at no charge to the physician), and generally charges the physician a fee for an agreed upon number of treatments or (ii) sells its lasers through a distributor or directly to a physician. In some cases, the Company and the customer stipulate to a quarterly or other periodic target of procedures to be performed, and accordingly revenue is recognized ratably over the period.

When the Company places a laser in a physician's office, it generally recognizes revenue based on the number of patient treatments performed, or purchased under a periodic commitment, by the physician. Amounts collected with respect to treatments to be performed through laser-access codes that are sold to physicians free of a periodic commitment, but not yet used, are deferred and recognized as a liability until the physician performs the treatment. Unused treatments remain an obligation of the Company because the treatments can only be performed on Company-owned equipment. Once the treatments are performed, this obligation has been satisfied.

The Company defers substantially all revenue from sales of treatment codes ordered by its customers within the last two weeks of the period in determining the amount of procedures performed by its physician-customers. Management believes this approach closely approximates the actual amount of unused treatments that existed at the end of a period.

Deferred revenue includes amounts received with respect to extended warranty maintenance, repairs and other billable services and amounts not yet recognized as revenues. Revenues with respect to such activities are deferred and recognized on a straight-line basis over the duration of the warranty period, the service period or when service is provided, as applicable to each service.

Inventories

Inventories are stated at the lower of cost or market. Cost is determined to be purchased cost for raw materials and the production cost (materials, labor and indirect manufacturing cost, including sub-contracted work components) for work-in-process and finished goods. For the Company's products, cost is determined on the first-in, first-out method. Throughout the laser manufacturing process, the related production costs are recorded within inventory. Work-in-process is immaterial, given the typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials.

The Company's equipment for the treatment of skin disorders (e.g. the XTRAC) will either (i) be placed in a physician's office and remain the property of the Company (at which date such equipment is transferred to property and equipment) or (ii) be sold to distributors or physicians directly. The cost to build a laser, whether for sale or for placement, is accumulated in inventory.

Reserves for slow moving and obsolete inventories are provided based on historical experience and product demand. Management evaluates the adequacy of these reserves periodically based on forecasted sales and market trends. As of September 30, 2015 reserves on inventory were $0. During the nine months ended September 30, 2015, the Company recorded a write-down of $4,818 towards the remaining inventory value of the MelaFind® systems, raw materials and components.

Property, Equipment and Depreciation

Property and equipment are recorded at cost, net of accumulated depreciation. Excimer lasers-in-service are depreciated on a straight-line basis over the estimated useful life of five years. For other property and equipment, depreciation is calculated on a straight-line basis over the estimated useful lives of the assets, primarily three to seven years for computer hardware and software, furniture and fixtures, and machinery and equipment. Leasehold improvements are amortized over the lesser of the useful lives or lease terms. Expenditures for major renewals and betterments to property and equipment are capitalized, while expenditures for maintenance and repairs are charged as an expense as incurred. Upon retirement or disposition, the applicable property amounts are deducted from the accounts and any gain or loss is recorded in the condensed consolidated statements of comprehensive loss. Useful lives are determined based upon an estimate of either physical or economic obsolescence or both.

Management evaluates the realizability of property and equipment based on estimates of undiscounted future cash flows over the remaining useful life of the asset. If the amount of such estimated undiscounted future cash flows is less than the net book value of the asset, the asset is written down to fair value. For the nine months ended September 30, 2015, the Company recorded a write-down of $920 on the remaining net book value of the MELAFind systems that were part of property and equipment (see Impairment of Long-Lived Assets and Intangibles).

Patent Costs and Licensed Technologies

Costs incurred to obtain or defend patents and licensed technologies are capitalized and amortized over the shorter of the remaining estimated useful lives or eight to 12 years. Core technology and product technology were recorded in connection with the asset purchase on June 22, 2015 and are being amortized on a straight-line basis over ten years for core technology and five years for product technology. (See Note 5, Patent and Licensed Technologies).

Management evaluates the recoverability of intangible assets based on estimates of undiscounted future cash flows over the remaining useful life of the asset. If the amount of such estimated undiscounted future cash flows is less than the net book value of the asset, the asset is written down to fair value. As of September 30, 2015, no such write-down was required. (See Impairment of Long-Lived Assets and Intangibles).

Other Intangible Assets

Other intangible assets were recorded in connection with the asset purchase on June 22, 2015. The assets that were determined to have definite useful lives are being amortized on a straight-line basis over ten years. Such assets primarily include customer relationships and trademarks. (See Note 7, Other Intangible Assets).

Management evaluates the recoverability of such other intangible assets based on estimates of undiscounted future cash flows over the remaining useful life of the asset. If the amount of such estimated undiscounted future cash flows is less than the net book value of the asset, the asset is written down to fair value. As of September 30, 2015 no such write-down was required. (See Impairment of Long-Lived Assets and Intangibles).

Accounting for the Impairment of Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company evaluates the carrying value of goodwill annually at the end of the calendar year and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, we may first perform an assessment qualitatively whether it is more likely than not that a reporting unit's carrying amount exceeds its fair value, referred to as a "step zero" approach. If, based on the review of the qualitative factors, we determine it is not more likely than not that the fair value of a reporting unit is less than its carrying value, we would bypass the two-step impairment test. If we conclude that it is more likely than not that a reporting unit's fair value is less than its carrying amount, we would perform the first step ("step one") of the two-step impairment test. Step 1 compares the fair value of the Group's reporting units to which goodwill was allocated to their carrying values. If the fair value of the reporting unit exceeds its carrying value, no further analysis is necessary. The reporting unit fair value is based upon consideration of various valuation methodologies, including guideline transaction multiples, multiples of current earnings, and projected future cash flows discounted at rates commensurate with the risk involved. If the carrying amount of the reporting unit exceeds its fair value, Step 2 must be completed to quantify the amount of impairment. Step 2 calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible assets, excluding goodwill, of the reporting unit, from the fair value of the reporting unit as determined in Step 1. The implied fair value of goodwill determined in this step is compared to the carrying value of goodwill. If the implied fair value of goodwill is less than the carrying value of goodwill, an impairment loss, equal to the difference, is recognized.

Impairment of Long-Lived Assets and Intangibles

Long-lived assets, such as property and equipment, and definite-lived intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the undiscounted cash flows attributable to the asset. If the carrying amount of an asset exceeds its undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds its fair value of the asset. During the nine months ended September 30, 2015 the Company recorded a write-down of $920 on the remaining net book value of the MelaFind systems that were part of property and equipment. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposed group classified as discontinued operations are presented separately in the appropriate asset and liability sections of the balance sheet.

Functional Currency

The currency of the primary economic environment in which the operations of the Company are conducted is the US dollar ("$" or "dollars"). Thus, the functional currency of the Company is the dollar except the operations of its foreign subsidiary, which is conducted in its local currency the Indian Rupee (INR). Substantially all of the Company's revenues are derived in dollars or in other currencies linked to the dollar. Purchases of most materials and components are carried out in, or linked to the dollar.

Balances denominated in, or linked to, foreign currencies are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the statement of comprehensive income (loss), the exchange rates applicable to the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses.

Assets and liabilities of the foreign subsidiary, whose functional currency is its local currency, are translated from its functional currency to U.S. dollars at the balance sheet date exchange rate. Income and expense items are translated at the average rate of exchange prevailing during the year. Translation adjustments are reflected in the consolidated balance sheets as a component of accumulated other comprehensive income (loss).

Fair Value Measurements

The Company measures and discloses fair value in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification 820, Fair Value Measurements and Disclosures ("ASC Topic 820"). ASC Topic 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

	•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
	•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
	•	Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.

The Company's recurring fair value measurements at September 30, 2015 and December 31, 2014 are as follows:

	Fair Value as of September 30, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 11)	$	9,535	$	-	$	-	$	9,535

	Fair Value as of December 31, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 11)	$	499	$	-	$	-	$	499

The fair value of cash and cash equivalents and short term bank deposits are based on their respective demand value, which are equal to the carrying value. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of the Company's warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures. The carrying value of all other short-term monetary assets and liabilities is estimated to be approximate to their fair value due to the short-term nature of these instruments. The fair value of the senior secured convertible debentures approximates its carrying value at September 30, 2015 due to the recent issuances of these instruments.

Several of the warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon change in control of the Company and other warrants contain full ratchet provisions that reduce the exercise price of the warrants in the event of a transaction resulting in the issuance of equity below the current price of the warrants. Therefore these warrants are classified as derivatives. These warrants have been recorded at their fair value using a binomial option pricing model and will be recorded at their respective fair value at each subsequent balance sheet date. See Note 11, Warrants, for additional discussion.

In addition to items that are measured at fair value on a recurring basis, there are also assets and liabilities that are measured at fair value on a nonrecurring basis. Assets and liabilities that are measured at fair value on a nonrecurring basis include certain long-lived assets, including goodwill. As such, the Company has determined that each of these fair value measurements reside within Level 3 of the fair value hierarchy.

Accrued Warranty Costs

The Company offers a standard warranty on product sales generally for a one to two-year period, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or meet customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold. Total accrued warranty is included in Other Accrued Liabilities and Other liabilities on the balance sheet. The activity in the warranty accrual during the nine months ended September 30, 2015 is summarized as follows:

	September 30, 2015
	(unaudited)
Accrual at beginning of year	$	48
Acquired in asset purchase		265
Additions charged to warranty expense		62
Expiring warranties/claimed satisfied		(110	)
Total		265
Less: current portion		(177	)
	$	88

Earnings Per Share

Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. The loss on the change in fair value of the warrant liability was considered in the diluted earnings per share calculation and was deemed to be antidilutive for all periods presented. Potential common stock equivalents outstanding as of September 30, 2015 and 2014 consist of common stock equivalents of common stock purchase warrants, senior secured convertible debentures, convertible preferred stock and common stock options, which are summarized as follows:

	September 30,
		2015	2014
Common stock equivalents of convertible debentures		46,521,127	5,847,955
Common stock purchase warrants		16,078,920	13,078,920
Common stock equivalents of convertible preferred stock		2,535,866	4,795,321
Common stock options		2,302,802	320,349
Total		67,438,715	24,042,545

Adoption of New Accounting Standards

In April 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity ("ASU 2014-08").

The amendments in ASU 2014-08 change the criteria for reporting discontinued operations while enhancing disclosures in this area. Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization's operations and financial results. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations.

The provisions of ASU 2014-08 were required to be applied in a prospective manner to disposals or classifications as held for sale components of an entity that occur with annual periods beginning on or after December 15, 2014 and interim periods within those years.

The adoption of ASU 2014-08 did not have a material impact on the Company's consolidated results of operations and financial condition.

Recently Issued Accounting Standards

In September 2015, the FASB issued ASU No. 2015-16, "Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments." The amendments in ASU 2015-16 require that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined, rather than retrospectively adjusting amounts previously reported. The amendments require that the acquirer record, in the same period's financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. Effective for public business entities for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The amendments should be applied prospectively to adjustments to provisional amounts that occur after the effective date with earlier application permitted for financial statements that have not been issued. The Company does not believe the adoption of this ASU will have a significant impact on the condensed consolidated financial statements.

In July, 2015, The FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11").

ASU 2015-11 outlines that inventory within the scope of its guidance be measured at the lower of cost and net realizable value. Inventory measured using last-in, first-out (LIFO) are not impacted by the new guidance. Prior to the issuance of ASU 2015-11, inventory was measured at the lower of cost or market (where market was defined as replacement cost, with a ceiling of net realizable value and floor of net realizable value less a normal profit margin).

For a public entity, the amendments in ASU 2015-11 are effective, in a prospective manner, for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period (the first quarter of fiscal year 2017 for the Company). Early adoption is permitted as of the beginning of an interim or annual reporting period.

The Company is in the process of assessing the impact, if any, of ASU 2015-11 on its consolidated financial statements.

In May 2014, The FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09").

ASU 2014-09 outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes mos current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 also requires entities to disclose sufficient information, both quantitative and qualitative, to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.

An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented with a possibility to elect certain practical expedients, or, 2. Retrospectively with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application. If an entity elects the latter transition method, it also should provide certain additional disclosures.

For a public entity, the amendments in ASU 2014-09 were to be effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. In July 2015, the FASB voted for a one year deferral of the effective date of ASU 2014-09 and issued an exposure draft. The new guidance will be effective for annual and interim periods beginning on or after December 15, 2017. Early application is not permitted. The Company is currently assessing the impact that adopting this new accounting guidance will have on its consolidated financial statements and footnote disclosures.

In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). ASU 2014-15 provides guidance on management's responsibility in evaluating whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 also provides guidance related to the required disclosures as a result of management evaluation. The amendments in ASU 2014-15 are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the new guidance to determine the impact the adoption of this guidance will have on the Company's results of operations, cash flows or financial condition.

In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs" (Subtopic 835-30). ASU No. 2015-03 provides guidance that will require debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, in the same manner as debt discounts, rather than as an asset. The standard is effective for reporting periods beginning after December 15, 2015 and early adoption is permitted. The Company is currently evaluating the new guidance to determine the impact the adoption of this guidance will have on the Company's results of operations, cash flows or financial condition.

Acquisition

9 Months Ended

Sep. 30, 2015

Acquisition [Abstract]

Acquisition

Note 2

Acquisition:

On June 22, 2015, the Company entered into an asset purchase agreement (the "Asset Purchase Agreement") with PhotoMedex Inc. and PhotoMedex Technology, Inc. pursuant to which the Company has purchased the XTRAC and VTRAC laser businesses from PhotoMedex, Inc. (the "Asset Purchase") for $42,528 in cash and assumed certain business-related liabilities. The purchased assets include all of the accounts receivable, inventory and fixed and intangible assets of the business.

The fair value of the assets acquired and liabilities assumed were based on management estimates and values with the assistance of an outside independent appraisal. The significant intangible assets to be recognized in the valuation are core and product technologies, tradenames and customer relationships. The estimated useful lives over which these assets will be amortized, utilizing the straight line method, are five years for product technologies and ten years for core technologies, tradenames and customer relationships. The following allocation of the aggregate fair value is preliminary and subject to adjustment based on the fair value of the assets acquired and the liabilities assumed. The Company estimated fair value of the intangibles and lasers placed in service was based on the income approach which estimated cash flow that utilize appropriate discount and capitalization rates and available market information. Estimates of future cash flows are based on a number of factors including the historical operating results, known trends and specific market and economic conditions. The fair value of the Company's remaining fixed assets was estimated based on the cost approach which estimated the cost to replace.

Current assets	$	7,233
Property, plant and equipment		14,340
Identifiable intangible assets		16,100
Other assets		45
Total assets assumed		37,718

Current liabilities		(3,945	)
Note payable		(57	)
Other long term liabilities		(116	)
Total liabilities assumed		(4,118	)

Net assets acquired	$	33,600

The purchase price exceeded the fair value of the net assets acquired by $8,928, which was recorded as goodwill.

The consolidated results of operations do not include any revenues or expenses related to XTRAC and VTRAC businesses on or prior to June 22, 2015, the date of the asset purchase. The Company's unaudited pro-forma results for the three and nine months ended September 30, 2015 and 2014 summarize the combined results in the following table, assuming the asset purchase had occurred on January 1, 2014 and after giving effect to the acquisition adjustments, including amortization of the tangible and long-lived intangible assets acquired in the transaction:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
	(unaudited)			(unaudited)			(unaudited)			(unaudited)

Net revenues	$	8,323		$	7,816		$	23,684		$	21,378
Net loss attributable to common shareholders	$	(12,186	)	$	(3,715	)	$	(33,662	)	$	(20,410	)
Net loss per basic and diluted share:	$	(1.29	)	$	(0.71	)	$	(4.21	)	$	(4.00	)
Shares used in calculating net loss per basic and diluted share:		9,442,022			5,216,290			7,994,012			5,108,418

These unaudited pro-forma results have been prepared for comparative purposes only and do not purport to be indicative of the results of operations which would have actually resulted had the acquisition occurred on January 1, 2014, nor to be indicative of future results of operations.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

+ Details

Inventories, net

9 Months Ended

Sep. 30, 2015

Inventories, net [Abstract]

Inventories, net

Note 3

Inventories, net:

	September 30, 2015		December 31, 2014
	(unaudited)
Raw materials and work in progress	$	3,329	$	2,553
Finished goods		586		4,131
Total inventories		3,915		6,684
Reserve for obsolete inventory		-		(870	)
Reserve for inventory repairs		-		(539	)
	$	3,915	$	5,275

Work-in-process is immaterial, given the Company's typically short manufacturing cycle, and therefore is disclosed in conjunction with raw materials. During the nine months ended September 30, 2015 the Company initiated plans to develop an updated version of the MelaFind system and, accordingly, determined that a majority of its existing inventory of MelaFind systems and related parts exceeded its requirements. As a result, the Company wrote-off the excess and obsolete MelaFind inventories of $5,688, including $870 previously reserved. In addition, as of December 31, 2014 the Company carried a repair reserve of $539 for the estimated cost to restore its MelaFind units to sellable condition, which was also eliminated with the write-off of the excess and obsolete MelaFind inventory.

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

Property and Equipment, net

9 Months Ended

Sep. 30, 2015

Property and Equipment, net [Abstract]

Property and Equipment, net

Note 4

Property and Equipment, net:

	September 30, 2015			December 31, 2014
	(unaudited)
Lasers placed-in-service	$	15,154		$	-
MELAFind systems		2,019			3,193
Equipment, computer hardware and software		1,244			1,084
Furniture and fixtures		2,054			1,969
Leasehold improvements		913			906
		21,384			7,152
Accumulated depreciation and amortization		(6,923	)		(5,191	)
Property and equipment, net	$	14,461		$	1,961

Depreciation and related amortization expense was $1,253 and $489 for the three months ended September 30, 2015 and 2014, respectively. Depreciation and related amortization expense was $1,891 and $1,367 for the nine months ended September 30, 2015 and 2014, respectively. During the second quarter of 2015, the Company evaluated the future cash flows of the MelaFind devices with remaining net book value, determined there was an impairment and recorded an impairment charge of $920.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

Patents and Licensed Technologies, net

9 Months Ended

Sep. 30, 2015

Patents and Licensed Technologies, Net [Abstract]

Patents and Licensed Technologies, net

Note 5

Patents and Licensed Technologies, net:

	September 30, 2015			December 31, 2014
	(unaudited)
Core technology	$	5,974		$	274

Product technology		2,000			-
		7,974			274
Accumulated amortization		(484	)		(237	)
Patents and licensed technologies, net	$	7,490		$	37

Related amortization expense was $244 and $1 for each of the three month ended September 30, 2015 and 2014. Related amortization expense was $247 and $4 for each of the nine months ended September 30, 2015 and 2014. The Core technology of $5,700 and Product technology of $2,000 are the core and product technologies acquired in the asset purchase of the XTRAC and VTRAC businesses and were recorded at their preliminary appraised fair market values at that date. Amortization of these intangibles is on a straight-line basis over 5 years for Product technology and 10 years for Core technology.

Estimated amortization expense for amortizable patents and licensed technologies assets for the future periods is as follows:

Last three months of 2015	$	238
2016		995
2017		995
2018		995
2019		995
Thereafter		3,272
Total	$	7,490

Other Intangible Assets

9 Months Ended

Sep. 30, 2015

Other Intangible Assets [Abstract]

Other Intangible Assets

Note 7

Other Intangible Assets:

Set forth below is a detailed listing of other definite-lived intangible assets:

	September 30, 2015
	(unaudited)
Customer relationships	$	6,900

Tradenames		1,500
		8,400
Accumulated amortization		(210	)
Other intangible assets, net	$	8,190

Related amortization expense was $210 for the three and nine months ended September 30, 2015. There was no related amortization expense for the period ended September 30, 2014. Customer Relationships embody the value to the Company of relationships that PhotoMedex, for the XTRAC products, had formed with its customers. Trademarks include the tradenames and various trademarks associated with the products (e.g. "XTRAC" and "VTRAC"). Amortization of these intangibles is on a straight-line basis over 10 years for each of the Customer relationships and Tradenames.

Estimated amortization expense for the above amortizable intangible assets for the future periods is as follows:

Last three months of 2015	$	210
2016		840
2017		840
2018		840
2019		840
Thereafter		4,620
Total	$	8,190

Senior Notes Payable

9 Months Ended

Sep. 30, 2015

Senior Notes Payable [Abstract]

Senior Notes Payable

Note 9

Senior Notes Payable:

In the following table is a summary of the Company's notes payable:

	September 30, 2015
	(unaudited)
Senior-secured notes payable, net of unamortized debt discount of $1,152	$	8,848

Senior Notes Payable

On June 22, 2015, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") and related financing documents with entities affiliated with existing institutional investors in the Company providing for the issuance of $42,500 aggregate principal amount (the "Financing") of senior secured notes (the "Notes"), senior secured convertible debentures, except for $500 of Debentures, (the "June 2015 debentures") and warrants (the "June 2015 Warrants") to purchase 3,000,000 shares of common stock at an exercise price of $0.75 per share. The Company sold $10,000 aggregate principal amount of Notes bearing interest at 9% per year with a maturity date of the earlier of 30 days after the Company obtains stockholder approval of stock issuances under the Debentures and the Warrants or November 30, 2015. The June 2015 Debentures are discussed further in Note 10, Convertible Debentures, below. The proceeds of the Financing were used to pay the purchase price of the assets acquired under the Asset Purchase Agreement.

Under the terms of the June 2015 Warrants, the issuances of shares of the common stock upon exercise of the Warrants were subject to stockholder approval of such issuances and an amendment to the Company's certificate of incorporation to increase the Company's authorized shares of common stock. The matter was approved by the stockholders at the Company's annual meeting held September 30, 2015. Accordingly, the Notes mature 30 days from that approval, October 30, 2015. The Notes are still outstanding, and while the Company is not in default with the terms of the notes, the notes are now on demand notes with an interest rate of 12% per year. The Company is currently evaluating alternatives, including discussions with lenders to refinance this debt.

The June 2015 Warrants contain anti-dilution provisions that allow for downward exercise price adjustments in certain situations. The warrants were treated as a derivative liability and a discount to the Notes and the discount is being amortized under the effective interest method over the repayment term of 5 months. As of September 30, 2015, the remaining unamortized warrant balance was $1,152.

The Company computed the value of the warrants using the binomial method. The key assumptions used to value the warrants are as follows:

	June 22, 2015	September 30, 2015

Number of shares underlying warrants	3,000,000	3,000,000
Exercise price	$0.75	$0.75
Share price	$1.38	$1.14
Fair value of warrants	$2,959	$2,561
Probability of stockholder approval	80.0%	100.0%
Volatility	90.0%	90.0%
Risk-free interest rate	1.62%	1.30%
Expected dividend yield	0%	0%
Expected warrant life	5 years	4.73 years

Convertible Debentures

9 Months Ended

Sep. 30, 2015

Convertible Debentures [Abstract]

Convertible Debentures

Note 10

Convertible Debentures:

In the following table is a summary of the Company's convertible debentures.

	September 30, 2015		December 31, 2014
	(unaudited)
Senior secured 2.25% convertible debentures, net of unamortized debt discount of $25,798	$	6,701	$	-
Senior secured 4% convertible debentures, net of unamortized debt discount of $4,146 and $8,410, respectively		4,672		5,001
Total convertible debt	$	11,373	$	5,001

The Company issued $32,500 aggregate principal amount of Debentures (June 2015 Debentures) that, subject to certain ownership limitations and stockholder approval conditions, will be convertible into 43,333,334 shares of Company common stock at an initial conversion price of $0.75 per share. The Debentures bear interest at the rate of 2.25% per year, and, unless previously converted, will mature on the five-year anniversary of the date of issuance, June 22, 2020. Under the terms of the Debentures and the June 2015 Warrants (noted above), the issuances of shares of the common stock upon conversion of the Debentures and upon exercise of the Warrants were subject to stockholder approval of such issuances and an amendment to the Company's certificate of incorporation to increase the Company's authorized shares of common stock. The Company received stockholder approval for these proposals, at the annual stockholders meeting held September 30, 2015.

The June 2015 Debentures include a beneficial conversion feature of $27,300 that was recorded as a discount to the debenture. On the date of issuance the beneficial conversion feature value was calculated as the difference resulting from subtracting the conversion price of $0.75 from $1.38, the opening market value of the Company's common stock following the announcement of the transaction, multiplied by the number of common shares into which the June 2015 Debentures are convertible. This discount will be amortized over the five year life of the Debentures. The embedded conversion feature contains an anti-dilution provision that allows for downward exercise price adjustments in certain situations. The embedded conversion feature was not bifurcated as it did not meet all of the elements of a derivative.

On July 21, 2014, the Company entered into a definitive Securities Purchase Agreement (the "Purchase Agreement") with institutional investors (the "Investors") providing for the issuance of Senior Secured Convertible Debentures in the aggregate principal amount of $15,000, due, subject to the terms therein, in July 2019 (the "July 2014 Debentures"), and warrants (the "July 2014 Series A Warrants") to purchase up to an aggregate of 6,198,832 shares of common stock, $0.001 par value per share, at an exercise price of $2.45 per share expiring in July 2019. The Debentures bear interest at an annual rate of 4%, payable quarterly or upon conversion into shares of common stock. The Debentures are convertible at any time into an aggregate of 5,847,955 shares of common stock at an initial conversion price of $2.565 per share. The Company's obligations under the Debentures are secured by a first priority lien on all of the Company's intellectual property pursuant to the terms of a security agreement ("Security Agreement") dated July 21, 2014 among the Company and the Investors. In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement with the Investors pursuant to which the Company was obligated to file a registration statement to register for resale the shares of Common Stock issuable upon conversion of the Series B Preferred Stock (See Note 11) and Debentures and upon exercise of the Warrants. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on August 19, 2014, which was declared effective by the SEC on October 20, 2014 (File No. 333-198249). Proceeds from the Debentures are being used for general working capital purposes.

For financial reporting purposes, the $15,000 funded by the Investors on July 21, 2014 was allocated first to the fair value of the obligation to issue the Warrants, amounting to $5,296, then to the intrinsic value of the beneficial conversion feature on the Debentures of $4,565. The balance was further reduced by the fair value of warrants issued to the placement agent for services rendered of $491, resulting in an initial carrying value of the Debentures of $4,647. The initial debt discount on the Debentures totaled $10,353 and is being amortized using the effective interest method over the five year life of the Debentures.

During the nine months ended September 30, 2015, the investors converted debentures amounting to $4,593 into 1,790,671 shares of common stock. The debt discount and deferred financing cost adjustment resulting from the conversions increased interest expense by $3,415 for the nine months ended September 30, 2015. As of September 30, 2015, the total outstanding amount of Debentures was $41,317.

Warrants

9 Months Ended

Sep. 30, 2015

Warrants [Abstract]

Warrants

Note 11

Warrants:

The Company accounts for warrants that have provisions that protect holders from a decline in the issue price of its common stock (or "down-round" provisions) as liabilities instead of equity. Down-round provisions reduce the exercise or conversion price of a warrant or convertible instrument if a company either issues equity shares for a price that is lower than the exercise or conversion price of those instruments or issues new warrants or convertible instruments that have a lower exercise or conversion price. Net settlement provisions allow the holder of the warrant to surrender shares underlying the warrant equal to the exercise price as payment of its exercise price, instead of physically exercising the warrant by paying cash. The Company evaluated whether warrants to acquire its common stock contain provisions that protect holders from declines in the stock price or otherwise could result in modification of the exercise price and/or shares to be issued under the respective warrant agreements based on a variable that is not an input to the fair value of a "fixed-for-fixed" option. In connection with the Senior secured notes (see Note 9), the Company issued warrants to purchase 3,000,000 shares of common stock. These warrants were classified as liabilities and had an initial fair value of $2,958. See the table below for the assumptions used.

As approved by the stockholders on September 30, 2015, the Company modified the terms of warrants held by the investors that participated in the June 2015 Debentures in excess of $5 million, which included reducing the exercise price of such warrants to $0.75 and adding down-round price protection provisions. These warrants had previously been classified and recorded in stockholders' equity. As a result of the modification these warrants now meet the definition of a derivative. The fair value of these warrants as of September 30, 2015 was $5,399 and have been reclassified to a warrant liability. As a result of the modification, the Company recorded a deemed dividend related to these warrants of $2,962, which was determined as the difference between the fair value of these warrants immediately before the modification and immediately after. The Company used the binomial method to value the warrants. (See assumptions used in the table below.) The following is a listing of the warrants modified:

Issue date	# of warrants		Original Exercise Price		New Exercise Price

7/24/14 Series A		4,288,500	$	2.45	$	0.75
7/24/14 Series B		4,795,321	$	2.45	$	0.75

The Company recognizes such warrants as liabilities at the fair value on each reporting date. The Company measured the fair value of these warrants as of September 30, 2015, and recorded other expense of $1,329 resulting from the increase of the liability associated with the fair value of the warrants for the three month period and recorded other expense of $679 resulting from the increase of the liability associated with the fair value of the warrants for the nine months ended September 30, 2015, respectively. The Company measured the fair value of these warrants as of September 30, 2014, and recorded other income of $2,108 resulting from the decrease of the liability associated with the fair value of the warrants for the three month period and recorded other income of $7,151 resulting from the decrease of the liability associated with the fair value of the warrants for the nine months ended September 30, 2014, respectively. The Company computed the value of the warrants using the binomial method. A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company's warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of September 30, 2015 and December 31, 2014 is as follows:

	September 30, 2015	June 22, 2015	December 31, 2014
	(unaudited)	(unaudited)
Stock price	$ 1.14	$ 1.38	$ 1.20
Volatility	90.00%	90.00%	72.90 – 88.10%
Risk-free interest rate	0.02% - 1.30%	1.62%	1.65%
Expected dividend yield	0%	0%	0%
Expected warrant life	0.32 – 4.73 years	5 years	4.10 – 4.33 years

Recurring Level 3 Activity and Reconciliation

The table below provides a reconciliation of the beginning and ending balances for the liability measured at fair value using significant unobservable inputs (Level 3). The table reflects gains and losses for the nine months for all financial liabilities categorized as Level 3 as of September 30, 2015.

Fair Value Measurements Using Significant Unobservable Inputs (Level 3):

Issuance Date	January 1, 2015		Initial Measurements		Increase (Decrease) in Fair Value			Reclassed from Equity		September 30, 2015

10/31/2013	$	233	$	-	$	309		$	-	$	542
2/5/2014		266		-		767			-		1,033
7/24/2014 Series A		-		-		-			3,452		3,452
7/24/2014 Series B		-		-		-			1,947		1,947
6/22/2015		-		2,958		(397	)		-		2,561

Total	$	499	$	2,958	$	679		$	5,399	$	9,535

Stockholders' Equity

9 Months Ended

Sep. 30, 2015

Stockholders' Equity [Abstract]

Stockholders' Equity

Note 12

Stockholders' Equity:

Preferred Stock

The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.10 per share with such designation, rights and preferences as may be determined from time to time by the Company's Board of Directors. There were 6,505 shares and 11,787 shares of Series B convertible preferred stock issued and outstanding on September 30, 2015 and December 31, 2014, respectively.

On February 5, 2014, pursuant to a securities purchase agreement, dated as of January 31, 2014, the Company sold an aggregate of 12,300 shares of Series A convertible preferred stock, par value $0.10 and a stated value of $1,000 per share convertible into 1,464,287 shares of common stock at an initial conversion price of $8.40, and warrants to purchase up to 1,329,731 shares of common stock for net proceeds of $11,458. The warrants have an exercise price of $7.40 per share, are immediately exercisable and have a term of five years. These warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative liability and recorded at fair value on the inception date of February 5, 2014. They will be recorded at their respective fair value at each subsequent balance sheet date.

In connection with this financing, the Company also granted resale registration rights with respect to the shares of common stock underlying the Series A preferred stock and the warrants pursuant to the terms of a Registration Rights Agreement. The purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of $3,420 during the nine months ended September 30, 2014. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014.

On July 24, 2014, in connection with the July 2014 Debentures (see Note 10, Convertible Debentures), the Company exchanged 12,300 shares of Series A convertible preferred stock issued on February 5, 2014 with 12,300 shares of Series B convertible preferred stock at a stated value of $1,000 per share convertible into common stock at an initial price of $2.565 per share. The preferred stock is immediately convertible into an aggregate of 4,795,321 shares of common stock. Holders of the Series B convertible preferred stock are entitled to dividends only in the event that dividends are paid on the common stock, and the preferred stock has no preferences over the common stock. In connection with the exchange, the Company issued the July 2014 Series B warrants to purchase up to an aggregate of 4,795,321 shares of common stock at an exercise price of $2.45 per share, expiring in January 2016. The July 2014 Series B warrants are immediately exercisable and are subject to certain ownership limitations.

The $12,300 preferred stock value was allocated first to the fair value of the July 2014 Series B warrants, which totaled $2,487, then to the intrinsic value of the beneficial conversion feature of $1,887. The amount of the beneficial conversion feature was considered to be a deemed dividend on the date of issuance to the Series B preferred stockholders. Pursuant to the terms of the Purchase Agreement, the Series A convertible preferred stock was redeemed from the proceeds of the Series B convertible preferred stock. In September 2014, the Company amended the registration statement related to the Series A preferred stock to deregister those shares that would have been issuable upon conversion of the Series A preferred stock had it not already been redeemed by the proceeds of the Series B preferred stock.

During nine months ending September 30, 2015, 5,282.5 shares of Series B preferred stock were converted into 2,059,455 shares of common stock.

Common Stock and Warrants

The Company is authorized to issue 150,000,000 shares of common stock with a par value of $0.001 per share. There were 9,887,358 and 6,037,232 issued and outstanding at September 30, 2015 and December 31, 2014, respectively.

On October 29, 2013, the Company entered into a securities purchase agreement with certain accredited investors in connection with a $6,000,000 registered offering of 422,819 shares of the Company's common stock, fully paid prefunded warrants (the "October 2013 Series B Warrants") to purchase up to 434,325 shares of its common stock and additional warrants ("October 2013 Series A Warrants") to purchase up to 685,715 shares of its common stock. The October 2013 Series A Warrants are exercisable beginning on May 1, 2014 at a price of $8.50 per share and expire on May 1, 2019. The October 2013 Series B Warrants were exercisable immediately for no additional consideration. The offering closed on October 31, 2013. The holders exercised all of the October 2013 Series B Warrants in March 2014.

The October 2013 Series A Warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative. Therefore, these warrants have been recorded at fair value at the inception date of October 31, 2013, and will be recorded at their respective fair values at each subsequent balance sheet date.

Outstanding common stock warrants consist of the following:

Issue Date	Expiration Date	Total Warrants	Exercise Price

4/26/2013	4/26/2018	69,321	$ 11.18
10/31/2013	4/30/2019	685,715	$ 0.75
2/5/2014	2/5/2019	1,329,731	$ 0.75
7/24/2014	7/24/2019	6,198,832	$ 0.75 - $ 2.45
7/24/2014	1/24/2016	4,795,321	$ 0.75
6/22/2015	6/22/2020	3,000,000	$ 0.75
		16,078,920

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

+ Details

Stock-based compensation

9 Months Ended

Sep. 30, 2015

Stock-based compensation [Abstract]

Stock-based compensation

Note 13

Stock-based compensation:

Stock awards under the Company's stock option plans have been granted with exercise prices that are no less than the market value of the stock on the date of the grant. Options granted under the plans are generally time-based or performance-based options and vesting varies accordingly. Options under the plans expire up to a maximum of ten years from the date of grant. Stock-based compensation to non-employee consultants, accounted for pursuant to FASB ASC 505-50-5, Equity, Equity Based Payments to Non-Employees, is granted for services rendered and is completely vested on the grant date.

The fair value of each option award granted during the period is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:

	Nine Months Ended September 30,
	2015	2014
Risk-free interest rate	1.75%	2.14 – 2.45%
Volatility	85.68%	75.51 – 73.87%
Expected dividend yield	0%	0%
Expected life	6.5 years	6.5 years
Estimated forfeiture rate	0%	0%

Stock-based compensation expense, primarily included in general and administration, for the three and nine months ended September 30, 2015 was $1,007 and $1,483, respectively. For the three and nine months ended September 30, 2014 stock-based compensation was $115 and $427, respectively. The nine months ended September 30, 2014, also included $20 of non-employee stock-based compensation. As of September 30, 2015 there was $535 in unrecognized compensation expense.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

Business Segments and Geographic Data

9 Months Ended

Sep. 30, 2015

Business Segments and Geographic Data [Abstract]

Business Segments and Geographic Data

Note 14

Business Segments and Geographic Data:

The Company organized its business into three operating segments to better align its organization based upon the Company's management structure, products and services offered, markets served and types of customers, as follows: The Dermatology Recurring Procedures segment derives its revenues from the XTRAC procedures performed by dermatologists. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The Dermatology Imaging segment generates revenues from the sale and usage of MelaFind devices. Management reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance. On June 22, 2015, the Company acquired the XTRAC and VTRAC businesses and has classified the revenues and expenses of this business to the two Dermatology Procedures segments. Accordingly, these revenues and operating expenses are included only for the period of June 23, 2015 through September 30, 2015. There are no corresponding revenues for the three and nine months ended September 30, 2014.

Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other financing income (expense), net is also not allocated to the operating segments.

The following tables reflect results of operations from our business segments for the periods indicated below:

Three Months Ended September 30, 2015 (unaudited)

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	7,033		$	1,189		$	101		$	8,323
Costs of revenues		2,326			607			109			3,042
Gross profit		4,707			582			( 8	)		5,281
Gross profit %		66.9	%		48.9	%		(7.9	%)		63.5	%

Allocated operating expenses:
Engineering and product development		348			31			92			471
Selling and marketing expenses		3,554			97			350			4,001

Unallocated operating expenses		-			-			-			3,132
		3,902			128			442			7,604
Income (loss) from operations		805			454			(450	)		(2,323	)

Interest expense, net		-			-			-			(5,577	)
Change in fair value of warrant liability		-			-			-			(1,329	)
Other income (expense), net		-			-			-			(5	)

Net income (loss)	$	805		$	454		$	(450	)	$	(9,234	)

Three Months Ended September 30, 2014 (unaudited)

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	-		$	-		$	218		$	218
Costs of revenues		-			-			1,560			1,560
Gross profit		-			-			(1,342	)		(1,342	)
Gross profit %		0.0	%		0.0	%		(615.6	%)		(615.6	%)

Allocated operating expenses:
Engineering and product development		-			-			345			345
Selling and marketing expenses		-			-			429			429

Unallocated operating expenses		-			-			-			1,885
		-			-			774			2,659
Loss from operations		-			-			(2,116	)		(4,001	)

Interest expense, net		-			-						(527	)
Change in fair value of warrant liability		-			-			-			2,108
Gain on sale of assets		-			-			-			11
Other income (expense), net		-			-			-			121

Net loss	$	-		$	-		$	(2,116	)	$	(2,288	)

Nine Months Ended September 30, 2015 (unaudited)

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	7,138		$	1,638		$	239		$	9,015
Costs of revenues		2,386			891			6,949			10,226
Gross profit		4,752			747			(6,710	)		( 1,211	)
Gross profit %		66.6	%		45.6	%		(2807.5	%)		(13.4	%)

Allocated operating expenses:
Engineering and product development		355			62			529			946
Selling and marketing expenses		3,723			127			2,134			5,984

Unallocated operating expenses		-			-			-			6,819
		4,078			189			2,663			13,749
Income (loss) from operations		674			558			(9,373	)		(14,960	)

Interest expense, net		-			-			-			(8,738	)
Change in fair value of warrant liability		-			-			-			(679	)
Other income (expense), net		-			-			-			23

Net income (loss)	$	674		$	558		$	(9,373	)	$	(24,354	)

Nine Months Ended September 30, 2014 (unaudited)

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	-		$	-		$	541		$	541
Costs of revenues		-			-			3,755			3,755
Gross profit		-			-			(3,214	)		(3,214	)
Gross profit %		0.0	%		0.0	%		(594.1	%)		(594.1	%)

Allocated operating expenses:
Engineering and product development		-			-			1,423			1,423
Selling and marketing expenses		-			-			2,366			2,366

Unallocated operating expenses		-			-			-			5,988
		-			-			3,789			9,777
Loss from operations		-			-			(7,003	)		(12,991	)

Interest expense, net		-			-			-			(528	)
Change in fair value of warrant liability		-			-			-			7,151
Gain on sale of assets		-			-			-			16
Other income (expense), net		-			-			-			131
Registration rights liquidated damages		-			-			-			(3,420	)

Net loss	$	-		$	-		$	(7,003	)	$	(9,641	)

For the three and nine months ended September 30, 2015 and 2014 there were no material net revenues attributable to any individual foreign country. Net revenues by geographic area were, as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Domestic	$	7,114	$	55	$	7,236	$	140
Foreign		1,209		163		1,779		401
	$	8,323	$	218	$	9,015	$	541

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

+ Details

Significant Customer Concentration	9 Months Ended
Significant Customer Concentration	Sep. 30, 2015
Significant Customer Concentration [Abstract]
Significant Customer Concentration	Note 15 Significant Customer Concentration: For the three months ended September 30, 2015, revenues from sales to the Company's international master distributor (GlobalMed Technologies) were $949, or 11.4%, of total revenues for such period. For the nine months ended September 30, 2015, revenues from sales to the Company's international master distributor were $1,385, or 15.4%, of total revenues for such period. At September 30, 2015, the accounts receivable balance from GlobalMed Technologies was $363, or 8.7%, of total net accounts receivable. No other customer represented more than 10% of total company revenues for the three and nine months ended September 30, 2015 and 2014.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References+ Details

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 16 Subsequent Events: During October 2015, investors converted debentures amounting to $676 into 296,035 shares of common stock. See Note 10. On November 4, 2015, the Company entered into consulting agreements with two of its directors, Jeffrey F. O'Donnell, Sr. and Samuel E. Navarro, the terms of which are the same. The agreements include compensation of $120 for each director and expire on June 30, 2016. On November 9, 2015, Robert W. Cook, Chief Financial Officer of the Company upon mutual agreement with the Board of Directors, resigned from his position as the Company's Chief Financial Officer, effective immediately. Mr. Cook will remain an employee of the Company at his current salary and benefits in the position of Senior Financial Advisor until January 15, 2016, subject to terms to be agreed upon in a Transition Services Agreement and Release, entered into as of November 11, 2015, which will entitle him to severance payments through October 6, 2016. Also on November 9, 2015, the Board appointed Christina L. Allgeier, age 43, as the Company's Chief Financial Officer, effective immediately. Ms. Allgeier, has served as the Company's Chief Accounting Officer. Ms. Allgeier graduated with a B.S. in accounting from Penn State University. Ms. Allgeier holds a license from the Commonwealth of Pennsylvania as a certified public accountant. For the past fifteen years Ms. Allgeier had been employed by PhotoMedex, Inc. (including a period with Surgical Laser Technologies, Inc. which was acquired by PhotoMedex in 2002). Ms. Allgeier served as Chief Accounting Officer of PhotoMedex from December 2011 until the purchase of the assets from PhotoMedex in June 2015. From November 2009 until the reverse acquisition of Radiancy, Inc. by PhotoMedex in December 2011, Ms. Allgeier served as Chief Financial Officer of PhotoMedex.

The Company (Policies)

9 Months Ended

Sep. 30, 2015

The Company [Abstract]

Liquidity

Accounting Principles

Principles of Consolidation

Property, Equipment and Depreciation

Patent Costs and Licensed Technologies

Other Intangible Assets

Accounting for the Impairment of Goodwill

Impairment of Long-Lived Assets and Intangibles

Functional Currency

Fair Value Measurements

	•	Level 1 – unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
	•	Level 2 – pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
	•	Level 3 – pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors

This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.

The Company's recurring fair value measurements at September 30, 2015 and December 31, 2014 are as follows:

	Fair Value as of September 30, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 11)	$	9,535	$	-	$	-	$	9,535

	Fair Value as of December 31, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 11)	$	499	$	-	$	-	$	499

Accrued Warranty Costs

	September 30, 2015
	(unaudited)
Accrual at beginning of year	$	48
Acquired in asset purchase		265
Additions charged to warranty expense		62
Expiring warranties/claimed satisfied		(110	)
Total		265
Less: current portion		(177	)
	$	88

Earnings Per Share

	September 30,
		2015	2014
Common stock equivalents of convertible debentures		46,521,127	5,847,955
Common stock purchase warrants		16,078,920	13,078,920
Common stock equivalents of convertible preferred stock		2,535,866	4,795,321
Common stock options		2,302,802	320,349
Total		67,438,715	24,042,545

Adoption of New Accounting Standards

The adoption of ASU 2014-08 did not have a material impact on the Company's consolidated results of operations and financial condition.

Recently Issued Accounting Standards

In July, 2015, The FASB issued Accounting Standards Update No. 2015-11, Simplifying the Measurement of Inventory (Topic 330) ("ASU 2015-11").

The Company is in the process of assessing the impact, if any, of ASU 2015-11 on its consolidated financial statements.

In May 2014, The FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASU 2014-09").

The Company (Tables)

9 Months Ended

Sep. 30, 2015

The Company [Abstract]

Fair Value Measurements on Recurring Basis

The Company's recurring fair value measurements at September 30, 2015 and December 31, 2014 are as follows:

	Fair Value as of September 30, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 11)	$	9,535	$	-	$	-	$	9,535

	Fair Value as of December 31, 2014		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability (Note 11)	$	499	$	-	$	-	$	499

Accrued Warranty Costs Activity

The activity in the warranty accrual during the nine months ended September 30, 2015 is summarized as follows:

	September 30, 2015
	(unaudited)
Accrual at beginning of year	$	48
Acquired in asset purchase		265
Additions charged to warranty expense		62
Expiring warranties/claimed satisfied		(110	)
Total		265
Less: current portion		(177	)
	$	88

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Potential common stock equivalents outstanding as of September 30, 2015 and 2014 consist of common stock equivalents of common stock purchase warrants, senior secured convertible debentures, convertible preferred stock and common stock options, which are summarized as follows:

	September 30,
		2015	2014
Common stock equivalents of convertible debentures		46,521,127	5,847,955
Common stock purchase warrants		16,078,920	13,078,920
Common stock equivalents of convertible preferred stock		2,535,866	4,795,321
Common stock options		2,302,802	320,349
Total		67,438,715	24,042,545

- Definition

Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References+ Details

Acquisition (Tables)

9 Months Ended

Sep. 30, 2015

Acquisition [Abstract]

Estimated Fair Value of Assets Acquired and Liabilities Assumed

The following allocation of the aggregate fair value is preliminary and subject to adjustment based on the fair value of the assets acquired and the liabilities assumed.The Company estimated fair value of the intangibles and lasers placed in service was based on the income approach which estimated cash flow that utilize appropriate discount and capitalization rates and available market information. Estimates of future cash flows are based on a number of factors including the historical operating results, known trends and specific market and economic conditions. The fair value of the Company's remaining fixed assets was estimated based on the cost approach which estimated the cost to replace.

Current assets	$	7,233
Property, plant and equipment		14,340
Identifiable intangible assets		16,100
Other assets		45
Total assets assumed		37,718

Current liabilities		(3,945	)
Note payable		(57	)
Other long term liabilities		(116	)
Total liabilities assumed		(4,118	)

Net assets acquired	$	33,600

Unaudited Pro-forma Results

The Company's unaudited pro-forma results for the three and nine months ended September 30, 2015 and 2014 summarize the combined results in the following table, assuming the asset purchase had occurred on January 1, 2014 and after giving effect to the acquisition adjustments, including amortization of the tangible and long-lived intangible assets acquired in the transaction:

	Three Months Ended September 30,						Nine Months Ended September 30,
	2015			2014			2015			2014
	(unaudited)			(unaudited)			(unaudited)			(unaudited)

Net revenues	$	8,323		$	7,816		$	23,684		$	21,378
Net loss attributable to common shareholders	$	(12,186	)	$	(3,715	)	$	(33,662	)	$	(20,410	)
Net loss per basic and diluted share:	$	(1.29	)	$	(0.71	)	$	(4.21	)	$	(4.00	)
Shares used in calculating net loss per basic and diluted share:		9,442,022			5,216,290			7,994,012			5,108,418

Property and Equipment, net (Tables)

9 Months Ended

Sep. 30, 2015

Property and Equipment, net [Abstract]

Summary of Property and Equipment, Net

Property and Equipment, net:

	September 30, 2015			December 31, 2014
	(unaudited)
Lasers placed-in-service	$	15,154		$	-
MELAFind systems		2,019			3,193
Equipment, computer hardware and software		1,244			1,084
Furniture and fixtures		2,054			1,969
Leasehold improvements		913			906
		21,384			7,152
Accumulated depreciation and amortization		(6,923	)		(5,191	)
Property and equipment, net	$	14,461		$	1,961

Patents and Licensed Technologies, net (Tables)

9 Months Ended

Sep. 30, 2015

Patents and Licensed Technologies, Net [Abstract]

Schedule of Patents and Licensed Technologies, Net

Patents and Licensed Technologies, net:

	September 30, 2015			December 31, 2014
	(unaudited)
Core technology	$	5,974		$	274

Product technology		2,000			-
		7,974			274
Accumulated amortization		(484	)		(237	)
Patents and licensed technologies, net	$	7,490		$	37

Estimated Amortization Expense for Amortizable Patents and Licensed Technologies Assets

Estimated amortization expense for amortizable patents and licensed technologies assets for the future periods is as follows:

Last three months of 2015	$	238
2016		995
2017		995
2018		995
2019		995
Thereafter		3,272
Total	$	7,490

Goodwill (Tables)

9 Months Ended

Sep. 30, 2015

Goodwill Disclosure [Abstract]

Schedule of Goodwill

Goodwill reflects the value or premium of the acquisition price in excess of the fair values assigned to specific tangible and intangible assets. Goodwill has an indefinite useful life and therefore is not amortized as an expense, but is reviewed annually for impairment of its fair value to the Company. Goodwill was recorded on the asset purchase of the XTRAC and VTRAC businesses as the purchase price exceeded the net assets of the business. (See Note 2, Acquisition.)

Balance at January 1, 2015	$	-
Additions for the asset purchase		8,928
Balance at September 30, 2015	$	8,928

Other Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2015

Other Intangible Assets [Abstract]

Schedule of Other Definite-lived Intangible Assets

Set forth below is a detailed listing of other definite-lived intangible assets:

	September 30, 2015
	(unaudited)
Customer relationships	$	6,900

Tradenames		1,500
		8,400
Accumulated amortization		(210	)
Other intangible assets, net	$	8,190

Finite-lived Intangible Assets Amortization Expense

Estimated amortization expense for the above amortizable intangible assets for the future periods is as follows:

Last three months of 2015	$	210
2016		840
2017		840
2018		840
2019		840
Thereafter		4,620
Total	$	8,190

Senior Notes Payable (Tables)

9 Months Ended

Sep. 30, 2015

Senior Notes Payable [Abstract]

Summary of Notes Payable

In the following table is a summary of the Company's notes payable:

	September 30, 2015
	(unaudited)
Senior-secured notes payable, net of unamortized debt discount of $1,152	$	8,848

Key Assumptions Used to Value the Warrants

The key assumptions used to value the warrants are as follows:

	June 22, 2015	September 30, 2015

Number of shares underlying warrants	3,000,000	3,000,000
Exercise price	$0.75	$0.75
Share price	$1.38	$1.14
Fair value of warrants	$2,959	$2,561
Probability of stockholder approval	80.0%	100.0%
Volatility	90.0%	90.0%
Risk-free interest rate	1.62%	1.30%
Expected dividend yield	0%	0%
Expected warrant life	5 years	4.73 years

Warrants (Tables)

9 Months Ended

Sep. 30, 2015

Warrants [Abstract]

Schedule of Fair Value Hierarchy

The following is a listing of the warrants modified:

Issue date	# of warrants		Original Exercise Price		New Exercise Price

7/24/14 Series A		4,288,500	$	2.45	$	0.75
7/24/14 Series B		4,795,321	$	2.45	$	0.75

Warrants Fair Value Assumptions

A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company's warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of September 30, 2015 and December 31, 2014 is as follows:

	September 30, 2015	June 22, 2015	December 31, 2014
	(unaudited)	(unaudited)
Stock price	$ 1.14	$ 1.38	$ 1.20
Volatility	90.00%	90.00%	72.90 – 88.10%
Risk-free interest rate	0.02% - 1.30%	1.62%	1.65%
Expected dividend yield	0%	0%	0%
Expected warrant life	0.32 – 4.73 years	5 years	4.10 – 4.33 years

Schedule of Derivative Warrant Liabilities

Fair Value Measurements Using Significant Unobservable Inputs (Level 3):

Issuance Date	January 1, 2015		Initial Measurements		Increase (Decrease) in Fair Value			Reclassed from Equity		September 30, 2015

10/31/2013	$	233	$	-	$	309		$	-	$	542
2/5/2014		266		-		767			-		1,033
7/24/2014 Series A		-		-		-			3,452		3,452
7/24/2014 Series B		-		-		-			1,947		1,947
6/22/2015		-		2,958		(397	)		-		2,561

Total	$	499	$	2,958	$	679		$	5,399	$	9,535

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References+ Details

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2015

Stockholders' Equity [Abstract]

Summary of Outstanding Common Stock Warrants

Outstanding common stock warrants consist of the following:

Issue Date	Expiration Date	Total Warrants	Exercise Price

4/26/2013	4/26/2018	69,321	$ 11.18
10/31/2013	4/30/2019	685,715	$ 0.75
2/5/2014	2/5/2019	1,329,731	$ 0.75
7/24/2014	7/24/2019	6,198,832	$ 0.75 - $ 2.45
7/24/2014	1/24/2016	4,795,321	$ 0.75
6/22/2015	6/22/2020	3,000,000	$ 0.75
		16,078,920

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References+ Details

Stock-based compensation (Tables)

9 Months Ended

Sep. 30, 2015

Stock-based compensation [Abstract]

Schedule of Fair Value of Each Option Award Granted

The fair value of each option award granted during the period is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:

	Nine Months Ended September 30,
	2015	2014
Risk-free interest rate	1.75%	2.14 – 2.45%
Volatility	85.68%	75.51 – 73.87%
Expected dividend yield	0%	0%
Expected life	6.5 years	6.5 years
Estimated forfeiture rate	0%	0%

Business Segments and Geographic Data (Tables)

9 Months Ended

Sep. 30, 2015

Business Segments and Geographic Data [Abstract]

Schedule of Segment Reporting Information by Segment

The following tables reflect results of operations from our business segments for the periods indicated below:

Three Months Ended September 30, 2015 (unaudited)

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	7,033		$	1,189		$	101		$	8,323
Costs of revenues		2,326			607			109			3,042
Gross profit		4,707			582			( 8	)		5,281
Gross profit %		66.9	%		48.9	%		(7.9	%)		63.5	%

Allocated operating expenses:
Engineering and product development		348			31			92			471
Selling and marketing expenses		3,554			97			350			4,001

Unallocated operating expenses		-			-			-			3,132
		3,902			128			442			7,604
Income (loss) from operations		805			454			(450	)		(2,323	)

Interest expense, net		-			-			-			(5,577	)
Change in fair value of warrant liability		-			-			-			(1,329	)
Other income (expense), net		-			-			-			(5	)

Net income (loss)	$	805		$	454		$	(450	)	$	(9,234	)

Three Months Ended September 30, 2014 (unaudited)

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	-		$	-		$	218		$	218
Costs of revenues		-			-			1,560			1,560
Gross profit		-			-			(1,342	)		(1,342	)
Gross profit %		0.0	%		0.0	%		(615.6	%)		(615.6	%)

Allocated operating expenses:
Engineering and product development		-			-			345			345
Selling and marketing expenses		-			-			429			429

Unallocated operating expenses		-			-			-			1,885
		-			-			774			2,659
Loss from operations		-			-			(2,116	)		(4,001	)

Interest expense, net		-			-						(527	)
Change in fair value of warrant liability		-			-			-			2,108
Gain on sale of assets		-			-			-			11
Other income (expense), net		-			-			-			121

Net loss	$	-		$	-		$	(2,116	)	$	(2,288	)

Nine Months Ended September 30, 2015 (unaudited)

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	7,138		$	1,638		$	239		$	9,015
Costs of revenues		2,386			891			6,949			10,226
Gross profit		4,752			747			(6,710	)		( 1,211	)
Gross profit %		66.6	%		45.6	%		(2807.5	%)		(13.4	%)

Allocated operating expenses:
Engineering and product development		355			62			529			946
Selling and marketing expenses		3,723			127			2,134			5,984

Unallocated operating expenses		-			-			-			6,819
		4,078			189			2,663			13,749
Income (loss) from operations		674			558			(9,373	)		(14,960	)

Interest expense, net		-			-			-			(8,738	)
Change in fair value of warrant liability		-			-			-			(679	)
Other income (expense), net		-			-			-			23

Net income (loss)	$	674		$	558		$	(9,373	)	$	(24,354	)

Nine Months Ended September 30, 2014 (unaudited)

	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Dermatology Imaging			TOTAL
Revenues	$	-		$	-		$	541		$	541
Costs of revenues		-			-			3,755			3,755
Gross profit		-			-			(3,214	)		(3,214	)
Gross profit %		0.0	%		0.0	%		(594.1	%)		(594.1	%)

Allocated operating expenses:
Engineering and product development		-			-			1,423			1,423
Selling and marketing expenses		-			-			2,366			2,366

Unallocated operating expenses		-			-			-			5,988
		-			-			3,789			9,777
Loss from operations		-			-			(7,003	)		(12,991	)

Interest expense, net		-			-			-			(528	)
Change in fair value of warrant liability		-			-			-			7,151
Gain on sale of assets		-			-			-			16
Other income (expense), net		-			-			-			131
Registration rights liquidated damages		-			-			-			(3,420	)

Net loss	$	-		$	-		$	(7,003	)	$	(9,641	)

Schedule of Net Revenues by Geographic Areas

For the three and nine months ended September 30, 2015 and 2014 there were no material net revenues attributable to any individual foreign country. Net revenues by geographic area were, as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2015		2014		2015		2014
Domestic	$	7,114	$	55	$	7,236	$	140
Foreign		1,209		163		1,779		401
	$	8,323	$	218	$	9,015	$	541

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details

The Company (Details) (USD $) In Thousands, except Share data, unless otherwise specified	9 Months Ended				9 Months Ended																9 Months Ended																0 Months Ended	9 Months Ended		0 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015 Channel	Sep. 30, 2014	Jun. 22, 2015	Dec. 31, 2014	Sep. 30, 2015 Common Stock Equivalents of Convertible Debentures [Member]	Sep. 30, 2014 Common Stock Equivalents of Convertible Debentures [Member]	Sep. 30, 2015 Common Stock Purchase Warrants [Member]	Sep. 30, 2014 Common Stock Purchase Warrants [Member]	Sep. 30, 2015 Common Stock Equivalents of Convertible Preferred Stock [Member]	Sep. 30, 2014 Common Stock Equivalents of Convertible Preferred Stock [Member]	Sep. 30, 2015 Common Stock Options [Member]	Sep. 30, 2014 Common Stock Options [Member]	Sep. 30, 2015 Fair Value, Measurements, Recurring [Member]	Dec. 31, 2014 Fair Value, Measurements, Recurring [Member]	Sep. 30, 2015 Fair Value, Measurements, Recurring [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	Dec. 31, 2014 Fair Value, Measurements, Recurring [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	Sep. 30, 2015 Fair Value, Measurements, Recurring [Member] Significant other Observable Inputs (Level 2) [Member]	Dec. 31, 2014 Fair Value, Measurements, Recurring [Member] Significant other Observable Inputs (Level 2) [Member]	Sep. 30, 2015 Fair Value, Measurements, Recurring [Member] Significant Unobservable Inputs (Level 3) [Member]	Dec. 31, 2014 Fair Value, Measurements, Recurring [Member] Significant Unobservable Inputs (Level 3) [Member]	Sep. 30, 2015 Patents and Licensed Technologies [Member]	Sep. 30, 2015 Core Technology [Member]	Sep. 30, 2015 Product Technology [Member]	Sep. 30, 2015 Other Intangible Assets [Member]	Sep. 30, 2015 Minimum [Member]	Sep. 30, 2015 Minimum [Member] Patents and Licensed Technologies [Member]	Sep. 30, 2015 Maximum [Member]	Sep. 30, 2015 Maximum [Member] Patents and Licensed Technologies [Member]	Sep. 30, 2015 Computer Hardware and Software [Member] Minimum [Member]	Sep. 30, 2015 Computer Hardware and Software [Member] Maximum [Member]	Sep. 30, 2015 Furniture and Fixtures [Member] Minimum [Member]	Sep. 30, 2015 Furniture and Fixtures [Member] Maximum [Member]	Sep. 30, 2015 Machinery and Equipment [Member] Minimum [Member]	Sep. 30, 2015 Machinery and Equipment [Member] Maximum [Member]	Sep. 30, 2015 2015 Financing [Member]	Jun. 22, 2015 2015 Financing [Member]	Jun. 22, 2015 XTRAC and VTRAC [Member]	Sep. 30, 2015 XTRAC and VTRAC [Member] Core Technology [Member]	Sep. 30, 2015 XTRAC and VTRAC [Member] Product Technology [Member]	Jun. 30, 2015 XTRAC and VTRAC [Member] 2015 Financing [Member]	Sep. 30, 2015 XTRAC and VTRAC [Member] 2015 Financing [Member]	Sep. 30, 2015 XTRAC and VTRAC [Member] Senior Secured Convertible Debentures [Member]	Sep. 30, 2015 XTRAC [Member] Systems	Dec. 31, 2014 XTRAC [Member] Patient Treatment
Business Acquisition [Line Items]
Acquisition price																																					$ 42,528
Number of systems placed in dermatologists offices																																											698
Number of laser treatments performed																																												300,000
Number of patients																																												19,000
Aggregate principal amount of debt																																			42,500	42,500					10,000	32,500
Interest rate																																									9.00%
Maturity date																																								Maturity date of the earlier of 30 days after the Company obtains stockholder approval of stock issuances under the Debentures and the Warrants or November 30, 2015.
Warrants issued and outstanding to purchase common stock (in shares)																																									3,000,000
Exercise price of warrants (in dollars per share)	$ 0.75		$ 0.75																																						$ 0.75
Number of shares issuable on conversion of debt (in shares)																																										43,333,334
Initial conversion price (in dollars per share)																																										$ 0.75
Interest rate																																										2.25%
Maturity period of debentures																																										5 years
Debentures secured by first priority lien																																										500
Issuance of common stock (in shares)																																									62,837,601
Liquidity [Abstract]
Accumulated deficit	(206,647)			(182,293)
Revenue Recognition [Abstract]
Number of distribution channels	2
Inventories [Abstract]
Reserves on inventory	0	870
Inventory write-offs	4,818	1,076
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years																												3 years	7 years	3 years	7 years	3 years	7 years
Write-down, property and equipment	920	0
Finite-Lived Intangible Assets [Line Items]
Estimated useful life																						10 years	5 years	10 years		8 years		12 years										10 years	5 years
Impairment of intangible assets																					0			0
Fair Value Assets And Liabilities, Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability (Note 11)													9,535	499	0	0	0	0	9,535	499
Product Warranty Liability [Line Items]
Standard warranty period																									1 year		2 years
Offered warranty period																									3 years		4 years
Product Warranty Accrual [Roll Forward]
Accrual at beginning of year	48
Acquired in asset purchase	265
Additions charged to warranty expense	62
Expiring warranties/claimed satisfied	(110)
Total	265
Less: current portion	(177)
Accrued warranty, non-current portion	$ 88
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential common stock equivalents (in shares)	67,438,715	24,042,545			46,521,127	5,847,955	16,078,920	13,078,920	2,535,866	4,795,321	2,302,802	320,349

Acquisition (Details) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended			9 Months Ended				0 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Sep. 30, 2015 Core Technology [Member]	Sep. 30, 2015 Product Technology [Member]	Sep. 30, 2015 Trade Names [Member]	Sep. 30, 2015 Customer Relationships [Member]	Jun. 22, 2015 XTRAC and VTRAC [Member]	Sep. 30, 2015 XTRAC and VTRAC [Member] Core Technology [Member]	Sep. 30, 2015 XTRAC and VTRAC [Member] Product Technology [Member]
Business Acquisition [Line Items]
Acquisition price										$ 42,528
Estimated useful life						10 years	5 years	10 years	10 years		10 years	5 years
Aggregate Fair Value of Assets Acquired and the Liabilities Assumed [Abstract]
Current assets	7,233		7,233
Property, plant and equipment	14,340		14,340
Identifiable intangible assets	16,100		16,100
Other assets	45		45
Total assets assumed	37,718		37,718
Current liabilities	(3,945)		(3,945)
Note payable	(57)		(57)
Other long term liabilities	(116)		(116)
Total liabilities assumed	(4,118)		(4,118)
Net assets acquired	33,600		33,600
Goodwill	8,928		8,928		0
Unaudited Pro-forma Results [Abstract]
Net revenues	8,323	7,816	23,684	21,378
Net loss attributable to common shareholders	$ (12,186)	$ (3,715)	$ (33,662)	$ (20,410)
Net loss per basic and diluted share: (in dollars per share)	$ (1.29)	$ (0.71)	$ (4.21)	$ (4.00)
Shares used in calculating net loss per basic and diluted share: (in shares)	9,442,022	5,216,290	7,994,012	5,108,418

Inventories, net (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Schedule of inventory [Abstract]
Raw materials and work in progress	$ 3,329	$ 2,553
Finished goods	586	4,131
Total inventories	3,915	6,684
Reserve for obsolete inventory	0	(870)
Reserve for inventory repairs	0	(539)
Inventories, net	3,915	5,275	5,275
Inventory [Line Items]
Excess and obsolete inventories write off	4,818	1,076
MELAFind Systems [Member]
Inventory [Line Items]
Excess and obsolete inventories write off	$ 5,688

Property and Equipment, net (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended					3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Sep. 30, 2015 Lasers Placed-In-Service [Member]	Dec. 31, 2014 Lasers Placed-In-Service [Member]	Jun. 30, 2015 MELAFind Systems [Member]	Sep. 30, 2015 MELAFind Systems [Member]	Dec. 31, 2014 MELAFind Systems [Member]	Sep. 30, 2015 Equipment, Computer Hardware and Software [Member]	Dec. 31, 2014 Equipment, Computer Hardware and Software [Member]	Sep. 30, 2015 Furniture and Fixtures [Member]	Dec. 31, 2014 Furniture and Fixtures [Member]	Sep. 30, 2015 Leasehold Improvements [Member]	Dec. 31, 2014 Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 21,384		$ 21,384		$ 7,152	$ 15,154	$ 0		$ 2,019	$ 3,193	$ 1,244	$ 1,084	$ 2,054	$ 1,969	$ 913	$ 906
Accumulated depreciation and amortization	(6,923)		(6,923)		(5,191)
Property and equipment, net	14,461		14,461		1,961
Depreciation and related amortization expense	1,253	489	1,891	1,367
Write-down, property and equipment			$ 920	$ 0				$ 920

- Definition

The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).

+ References+ Details

Patents and Licensed Technologies, net (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization		$ 0		$ 0
Patents and licensed technologies, net	7,490		7,490		37
Amortization expense	244	1	247	4
Estimated amortization expense [Abstract]
Patents and licensed technologies, net	7,490		7,490		37
Core Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	5,974		5,974		274
Estimated useful life			10 years
Core Technology [Member] \| XTRAC and VTRAC [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, net	5,700		5,700
Estimated useful life			10 years
Estimated amortization expense [Abstract]
Patents and licensed technologies, net	5,700		5,700
Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	2,000		2,000		0
Estimated useful life			5 years
Product Technology [Member] \| XTRAC and VTRAC [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, net	2,000		2,000
Estimated useful life			5 years
Estimated amortization expense [Abstract]
Patents and licensed technologies, net	2,000		2,000
Patents and Licensed Technologies [Member]
Finite-Lived Intangible Assets [Line Items]
Patents and licensed technologies, gross	7,974		7,974		274
Accumulated amortization	(484)		(484)		(237)
Patents and licensed technologies, net	7,490		7,490		37
Estimated amortization expense [Abstract]
Last three months of 2015	238		238
2016	995		995
2017	995		995
2018	995		995
2019	995		995
Thereafter	3,272		3,272
Patents and licensed technologies, net	$ 7,490		$ 7,490		$ 37

Goodwill (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2015
Goodwill [Roll Forward]
Balance at beginning of period	$ 0
Additions for the asset purchase	8,928
Balance at end of period	8,928
Accumulated impairment losses of goodwill	$ 0

Other Intangible Assets (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization		$ 0		$ 0
Other intangible assets, net	8,190		8,190		0
Amortization expense of other intangible assets	244	1	247	4
Estimated amortization expense [Abstract]
Other intangible assets, net	8,190		8,190		0
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets, gross	6,900		6,900
Estimated useful life			10 years
Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets, gross	1,500		1,500
Estimated useful life			10 years
Customer Relationships and Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangible assets, gross	8,400		8,400
Accumulated amortization	(210)		(210)
Other intangible assets, net	8,190		8,190
Amortization expense of other intangible assets	210	0	210	0
Estimated amortization expense [Abstract]
Last three months of 2015	210		210
2016	840		840
2017	840		840
2018	840		840
2019	840		840
Thereafter	4,620		4,620
Other intangible assets, net	$ 8,190		$ 8,190

Other Accrued Liabilities (Details) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2015	Dec. 31, 2014
Other Accrued Liabilities [Abstract]
Accrued warranty, current, see Note 1	$ 177	$ 48
Accrued compensation, including commissions and vacation	965	55
Other accrued liabilities	778	856
Total other accrued liabilities	$ 1,920	$ 959

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

Senior Notes Payable (Details) (USD $) In Thousands, except Share data, unless otherwise specified	0 Months Ended	9 Months Ended	12 Months Ended
	Jun. 22, 2015	Sep. 30, 2015	Dec. 31, 2014	Jun. 22, 2015
Debt Instrument [Line Items]
Senior-secured notes payable, net of unamortized debt discount of $1,152		$ 8,848	$ 0
Assumptions used to value the warrants [Abstract]
Number of shares underlying warrants (in shares)		3,000,000		3,000,000
Exercise price (in dollars per share)		$ 0.75		$ 0.75
Share price (in dollars per share)		$ 1.14		$ 1.38
Fair value of warrants		2,561		2,959
Probability of stockholder approval		100.00%		80.00%
Volatility	90.00%	90.00%
Risk-free interest rate	1.62%	1.30%
Expected dividend yield	0.00%	0.00%
Expected warrant life	5 years	4 years 8 months 23 days
Warrant [Member]
Debt Instrument [Line Items]
Unamortized debt discount		1,152
Assumptions used to value the warrants [Abstract]
Exercise price (in dollars per share)		$ 0.75
Share price (in dollars per share)		$ 1.14	$ 1.20	$ 1.38
Fair value of warrants		2,958
Volatility	90.00%	90.00%
Risk-free interest rate	1.62%		1.65%
Expected dividend yield	0.00%	0.00%	0.00%
Expected warrant life	5 years
Financing 2015 [Member]
Debt Instrument [Line Items]
Aggregate principal amount of debt	42,500	42,500		42,500
Senior Secured Notes Payable [Member]
Debt Instrument [Line Items]
Senior-secured notes payable, net of unamortized debt discount of $1,152		8,848
Unamortized debt discount		1,152
Number of days for stockholders approval considered for maturity date		30 days
Interest rate		12.00%
Warrants liability repayment terms		5 months
Senior Secured Notes Payable [Member] \| Financing 2015 [Member]
Debt Instrument [Line Items]
Aggregate principal amount of debt				10,000
Number of days for stockholders approval considered for maturity date	30 days
Interest rate				9.00%
Debentures [Member] \| Financing 2015 [Member]
Debt Instrument [Line Items]
Senior secured convertible debentures	$ 500	$ 500		$ 500

Convertible Debentures (Details) (USD $) In Thousands, except Share data, unless otherwise specified	9 Months Ended			9 Months Ended				9 Months Ended				0 Months Ended	9 Months Ended
	Sep. 30, 2015	Jun. 22, 2015	Dec. 31, 2014	Sep. 30, 2015 Series A Warrants [Member]	Jul. 24, 2014 Series A Warrants [Member]	Jul. 21, 2014 Series A Warrants [Member]	Oct. 29, 2013 Series A Warrants [Member]	Sep. 30, 2015 Senior Secured 2.25% Convertible Debentures [Member]	Dec. 31, 2014 Senior Secured 2.25% Convertible Debentures [Member]	Sep. 30, 2015 Senior Secured 2.25% Convertible Debentures [Member] Maximum [Member]	Sep. 30, 2015 Senior Secured 2.25% Convertible Debentures [Member] Minimum [Member]	Jul. 21, 2014 Senior Secured 4% Convertible Debentures [Member]	Sep. 30, 2015 Senior Secured 4% Convertible Debentures [Member]	Dec. 31, 2014 Senior Secured 4% Convertible Debentures [Member]	Jul. 21, 2014 Senior Secured 4% Convertible Debentures [Member]
Debt Instrument [Line Items]
Total convertible debt	$ 11,373		$ 5,001					$ 6,701	$ 0				$ 4,672	$ 5,001
Debt instrument, unamortized discount								25,798					4,146	8,410	10,353
Interest rate								2.25%					4.00%
Aggregate principal amount of debt								32,500					15,000		15,000
Number of warrants to purchase common stock (in shares)				6,198,832		6,198,832	685,715
Number of shares debt convertible (in shares)								43,333,334				5,847,955	5,847,955
Initial conversion price (in dollars per share)								$ 0.75		$ 1.38	$ 0.75		$ 2.565		$ 2.565
Debt instrument, maturity period								5 years					5 years
Exercise price of warrants (in dollars per share)	$ 0.75	$ 0.75		$ 0.75	$ 2.45	$ 2.45	$ 8.50
Debt instrument, convertible, beneficial conversion feature								27,300				4,565	4,565
Maturity date								Jun. 22, 2020					Jul. 01, 2019
Warrants expiration date				Jul. 01, 2019
Common stock, par value (in dollars per share)	$ 0.001		$ 0.001	$ 0.001		$ 0.001
Fair value of warrants	2,561	2,959													5,296
Fair value of warrants adjustment (income) expense												491
Debt instrument initial carrying amount															4,647
Debentures converted in shares of common stock, value	4,593
Debt conversion, converted instrument, issued (in shares)	1,790,671
Interest expense on debt	3,415
Debentures outstanding amount	$ 41,317

Warrants (Details) (USD $)	0 Months Ended	3 Months Ended		9 Months Ended			9 Months Ended				9 Months Ended			0 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended		9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended
Warrants (Details) (USD $)	Jun. 22, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Jun. 22, 2015	Sep. 30, 2015 7/24/2014 Series A [Member]	Jul. 24, 2014 7/24/2014 Series A [Member]	Jul. 21, 2014 7/24/2014 Series A [Member]	Oct. 29, 2013 7/24/2014 Series A [Member]	Sep. 30, 2015 7/24/2014 Series B [Member]	Jul. 24, 2014 7/24/2014 Series B [Member]	Oct. 29, 2013 7/24/2014 Series B [Member]	Jun. 22, 2015 Warrant [Member]	Sep. 30, 2015 Warrant [Member]	Sep. 30, 2014 Warrant [Member]	Sep. 30, 2015 Warrant [Member]	Sep. 30, 2014 Warrant [Member]	Dec. 31, 2014 Warrant [Member]	Jun. 22, 2015 Warrant [Member]	Sep. 30, 2015 Warrant [Member] Minimum [Member]	Dec. 31, 2014 Warrant [Member] Minimum [Member]	Sep. 30, 2015 Warrant [Member] Maximum [Member]	Dec. 31, 2014 Warrant [Member] Maximum [Member]	Sep. 30, 2015 Warrant [Member] Level 3 [Member]	Sep. 30, 2015 Warrant [Member] Level 3 [Member] 10/31/2013 [Member]	Sep. 30, 2015 Warrant [Member] Level 3 [Member] 2/5/2014 [Member]	Sep. 30, 2015 Warrant [Member] Level 3 [Member] 7/24/2014 Series A [Member]	Sep. 30, 2015 Warrant [Member] Level 3 [Member] 7/24/2014 Series B [Member]	Sep. 30, 2015 Warrant [Member] Level 3 [Member] 6/22/2015 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrants issued to purchase common stock (in shares)							6,198,832		6,198,832	685,715			434,325		3,000,000		3,000,000
Fair value of warrants		$ 2,561,000		$ 2,561,000		$ 2,959,000									$ 2,958,000		$ 2,958,000
Debentures in excess held by the investors															5,000,000		5,000,000
Exercise price of warrants (in dollars per share)		$ 0.75		$ 0.75		$ 0.75	$ 0.75	$ 2.45	$ 2.45	$ 8.50	$ 0.75	$ 2.45			$ 0.75		$ 0.75
Modification of warrants				5,399,000													5,399,000
Deemed dividend		2,962,000	0	2,962,000	0												2,962,000
Fair value of warrants adjustment (income) expense															1,329,000	(2,108,000)	679,000	(7,151,000)
Number of warrants							4,288,500				4,795,321
Fair Value Assumptions [Abstract]
Stock price (in dollars per share)		$ 1.14		$ 1.14		$ 1.38									$ 1.14		$ 1.14		$ 1.20	$ 1.38
Volatility	90.00%			90.00%										90.00%			90.00%					72.90%		88.10%
Risk-free interest rate	1.62%			1.30%										1.62%					1.65%		0.02%		1.30%
Expected dividend yield	0.00%			0.00%										0.00%			0.00%		0.00%
Expected warrant life	5 years			4 years 8 months 23 days										5 years							0 years 3 months 25 days	4 years 1 month 6 days	4 years 8 months 23 days	4 years 3 months 29 days
Fair Value Measurements Using Significant Unobservable Inputs (Level 3) [Abstract]
Balance as beginning of period																									499,000	233,000	266,000	0	0	0
Initial measurements																									2,958,000	0	0	0	0	2,958,000
Increase (decrease) in fair value																									679,000	309,000	767,000	0	0	(397,000)
Reclassed from equity																									5,399,000	0	0	3,452,000	1,947,000	0
Balance as end of period																									$ 9,535,000	$ 542,000	$ 1,033,000	$ 3,452,000	$ 1,947,000	$ 2,561,000

Stockholders' Equity (Details) (USD $) In Thousands, except Share data, unless otherwise specified	0 Months Ended	9 Months Ended												9 Months Ended						9 Months Ended		0 Months Ended	9 Months Ended			0 Months Ended				0 Months Ended
	Oct. 29, 2013	Sep. 30, 2015	Sep. 30, 2014	Jun. 22, 2015	Dec. 31, 2014	Oct. 29, 2013	Sep. 30, 2015 Series A Warrants [Member]	Jul. 24, 2014 Series A Warrants [Member]	Jul. 21, 2014 Series A Warrants [Member]	Oct. 29, 2013 Series A Warrants [Member]	Sep. 30, 2015 Series B warrants [Member]	Jul. 24, 2014 Series B warrants [Member]	Oct. 29, 2013 Series B warrants [Member]	Sep. 30, 2015 Common Stock Warrant One [Member]	Sep. 30, 2015 Common Stock Warrant Two [Member]	Sep. 30, 2015 Common Stock Warrant Three [Member]	Sep. 30, 2015 Common Stock Warrant Four [Member]	Sep. 30, 2015 Common Stock Warrant Four [Member] Minimum [Member]	Sep. 30, 2015 Common Stock Warrant Four [Member] Maximum [Member]	Sep. 30, 2015 Common Stock Warrant Five [Member]	Sep. 30, 2015 Common Stock Warrant Six [Member]	Jul. 24, 2014 Series B Preferred Stock [Member]	Sep. 30, 2015 Series B Preferred Stock [Member]	Dec. 31, 2014 Series B Preferred Stock [Member]	Jul. 24, 2014 Series B Preferred Stock [Member]	Jul. 24, 2014 Series A Preferred Stock [Member]	Feb. 05, 2014 Series A Preferred Stock [Member]	Sep. 30, 2015 Common Stock [Member]	Jul. 24, 2014 Common Stock [Member]	Feb. 05, 2014 Common Stock Equivalents of Convertible Preferred Stock [Member]	Feb. 05, 2014 Common Stock Equivalents of Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized (in shares)		10,000,000			10,000,000
Preferred stock, par value (in dollars per share)		$ 0.10			$ 0.10																						$ 0.10				$ 0.10
Preferred stock, shares issued (in shares)		6,505			11,787																		6,505	11,787			12,300				12,300
Preferred stock, shares outstanding (in shares)		6,505			11,787																		6,505	11,787
Number of preferred stock converted (in shares)																						12,300.0	5,282.5			12,300.0
Number of shares issued upon conversion (in shares)																												2,059,455	4,795,321		1,464,287
Conversion of convertible preferred stock, stated value (in dollars per share)																									$ 1,000		$ 1,000
Initial conversion price (in dollars per share)																									$ 2.565						$ 8.40
Proceeds from issuance of warrants																														$ 11,458
Warrant term																														5 years
Liquidated damages paid to purchasers			3,420
Total preferred stock value		1			1																				2,487
Intrinsic value of beneficial conversion feature																									1,887
Common stock, shares authorized (in shares)		150,000,000			150,000,000
Common stock, par value (in dollars per share)		$ 0.001			$ 0.001		$ 0.001		$ 0.001
Common stock, shares issued (in shares)		9,887,358			6,037,232	422,819
Common stock, shares outstanding (in shares)		9,887,358			6,037,232
Proceeds from issuance of common stock	$ 6,000,000	$ 0	$ 11,458
Class of Warrant or Right [Line Items]
Issue Date														Apr. 26, 2013	Oct. 31, 2013	Feb. 05, 2014	Jul. 24, 2014			Jul. 24, 2014	Jun. 22, 2015
Expiration Date														Apr. 26, 2018	Apr. 30, 2019	Feb. 05, 2019	Jul. 24, 2019			Jan. 24, 2016	Jun. 22, 2020
Total Warrants (in shares)		16,078,920												69,321	685,715	1,329,731	6,198,832			4,795,321	3,000,000
Exercise price (in dollars per share)		$ 0.75		$ 0.75			$ 0.75	$ 2.45	$ 2.45	$ 8.50	$ 0.75	$ 2.45		$ 11.18	$ 0.75	$ 0.75		$ 0.75	$ 2.45	$ 0.75	$ 0.75				$ 2.45						$ 7.40
Warrants issued and outstanding to purchase common stock (in shares)							6,198,832		6,198,832	685,715			434,325												4,795,321						1,329,731

Stock-based compensation (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Stock-based compensation expense			$ 1,483	$ 447
Non-employee stock-based compensation				20
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate			1.75%
Risk-free interest rate - Minimum				2.14%
Risk-free interest rate - Maximum				2.45%
Volatility			85.68%
Volatility - Minimum				75.51%
Volatility - Maximum				73.87%
Expected dividend yield			0.00%	0.00%
Expected life			6 years 6 months	6 years 6 months
Estimated forfeiture rate			0.00%	0.00%
Stock-based compensation expense	1,007	115	1,483	427
Unrecognized compensation expense	$ 535		$ 535
Stock Options [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiry period of option			10 years

Business Segments and Geographic Data (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015 Segment	Sep. 30, 2014
Segment Reporting Information [Line Items]
Number of operating segments			3
Number of dermatology procedures segments			2
Revenues	$ 8,323	$ 218	$ 9,015	$ 541
Cost of revenues	3,042	1,560	10,226	3,755
Gross profit	5,281	(1,342)	(1,211)	(3,214)
Gross profit %	63.50%	(615.60%)	(13.40%)	(594.10%)
Allocated operating expenses [Abstract]
Engineering and product development	471	345	946	1,423
Selling and marketing expenses	4,001	429	5,984	2,366
Unallocated operating expenses	3,132	1,885	6,819	5,988
Total operating expenses	7,604	2,659	13,749	9,777
Income (loss) from operations	(2,323)	(4,001)	(14,960)	(12,991)
Interest expense, net	(5,577)	(527)	(8,738)	(528)
Change in fair value of warrant liability	(1,329)	2,108	(679)	7,151
Gain on sale of assets	0	11	0	16
Other income (expense), net	(5)	121	23	131
Registration rights liquidated damages			0	(3,420)
Net income (loss)	(9,234)	(2,288)	(24,354)	(9,641)
Dermatology Recurring Procedures [Member]
Segment Reporting Information [Line Items]
Revenues		0		0
Dermatology Procedures Equipment [Member]
Segment Reporting Information [Line Items]
Revenues		0		0
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Segment Reporting Information [Line Items]
Revenues	7,033	0	7,138	0
Cost of revenues	2,326	0	2,386	0
Gross profit	4,707	0	4,752	0
Gross profit %	66.90%	0.00%	66.60%	0.00%
Allocated operating expenses [Abstract]
Engineering and product development	348	0	355	0
Selling and marketing expenses	3,554	0	3,723	0
Unallocated operating expenses	0	0	0	0
Total operating expenses	3,902	0	4,078	0
Income (loss) from operations	805	0	674	0
Interest expense, net	0	0	0	0
Change in fair value of warrant liability	0	0	0	0
Gain on sale of assets		0		0
Other income (expense), net	0	0	0	0
Registration rights liquidated damages				0
Net income (loss)	805	0	674	0
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Segment Reporting Information [Line Items]
Revenues	1,189	0	1,638	0
Cost of revenues	607	0	891	0
Gross profit	582	0	747	0
Gross profit %	48.90%	0.00%	45.60%	0.00%
Allocated operating expenses [Abstract]
Engineering and product development	31	0	62	0
Selling and marketing expenses	97	0	127	0
Unallocated operating expenses	0	0	0	0
Total operating expenses	128	0	189	0
Income (loss) from operations	454	0	558	0
Interest expense, net	0	0	0	0
Change in fair value of warrant liability	0	0	0	0
Gain on sale of assets		0		0
Other income (expense), net	0	0	0	0
Registration rights liquidated damages				0
Net income (loss)	454	0	558	0
Operating Segments [Member] \| Dermatology Imaging [Member]
Segment Reporting Information [Line Items]
Revenues	101	218	239	541
Cost of revenues	109	1,560	6,949	3,755
Gross profit	(8)	(1,342)	(6,710)	(3,214)
Gross profit %	(7.90%)	(615.60%)	(2807.50%)	(594.10%)
Allocated operating expenses [Abstract]
Engineering and product development	92	345	529	1,423
Selling and marketing expenses	350	429	2,134	2,366
Unallocated operating expenses	0	0	0	0
Total operating expenses	442	774	2,663	3,789
Income (loss) from operations	(450)	(2,116)	(9,373)	(7,003)
Interest expense, net	0		0	0
Change in fair value of warrant liability	0	0	0	0
Gain on sale of assets		0		0
Other income (expense), net	0	0	0	0
Registration rights liquidated damages				0
Net income (loss)	(450)	(2,116)	(9,373)	(7,003)
Reportable Geographical Components [Member] \| Domestic [Member]
Segment Reporting Information [Line Items]
Revenues	7,114	55	7,236	140
Reportable Geographical Components [Member] \| Foreign [Member]
Segment Reporting Information [Line Items]
Revenues	$ 1,209	$ 163	$ 1,779	$ 401

Significant Customer Concentration (Details) (Customer Concentration Risk [Member], USD $) In Thousands, unless otherwise specified	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Revenue [Member]
Product Information [Line Items]
Revenues	$ 949	$ 1,385
Concentration risk percentage	11.40%	15.40%
Accounts Receivable [Member]
Product Information [Line Items]
Accounts receivable	$ 363	$ 363
Concentration risk percentage		8.70%

Subsequent Events (Details) (USD $) In Thousands, except Share data, unless otherwise specified	9 Months Ended	0 Months Ended		0 Months Ended
	Sep. 30, 2015	Oct. 31, 2015 Subsequent Event [Member]	Nov. 04, 2015 Subsequent Event [Member] Employee	Nov. 04, 2015 Subsequent Event [Member] Jeffrey F. O'Donnell, Sr. [Member]	Nov. 04, 2015 Subsequent Event [Member] Samuel E. Navarro [Member]
Subsequent Events [Line Items]
Debentures converted in shares of common stock, value	$ 4,593	$ 676
Debentures converted in shares of common stock (in shares)	1,790,671	296,035
Number of directors			2
Employee compensation				$ 120	$ 120

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2015
Cash Flows From Investing Activities:
Cash acquired	$ 0